RMC-6236 to advance to Ph 3 testing in pancreatic cancer following encouraging results from a Ph 1 study

“RMC-6236 is the first targeted investigational drug designed to directly inhibit all major forms of oncogenic RAS, the major drivers of PDAC. RMC-6236 has shown compelling anti-tumor activity and a favorable safety profile in a broad population of patients with previously treated PDAC, and has potential to become an important new treatment option.  Extensive efforts are ongoing toward launching RASolute 302, a global, randomized Phase 3 clinical trial comparing RMC-6236 to chemotherapy as 2L treatment of patients with metastatic PDAC.”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib